Patent ID: 6153604
Filing Date: 2000-11-28
Classification: A61P,C07C,C07D

Abstract:
A method of treating a disease of the nervous system in which the pathophysiology of the disorder involves excessive excitation of nerve cells by agonists of NMDA receptors, comprising administering to a mammal exhibiting symptoms of the disease or that is susceptible to the disease a treatment effective amount of a compound of the following formula I: ##STR9## wherein R is substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaromatic or heterocyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 heteroatoms;R.sup.1 and R.sup.2 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 hetero atoms;R.sup.3, R.sup.4, and each R.sup.5 substituent are each independently halogen, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, or substituted or unsubstituted aralkyl; n is an integer of from 0-3; or a pharmaceutically acceptable salt thereof, with the exclusion of N-(2,4-di-iodo-5-hydroxyphenyl)-N'-(2-tolyl)-guanidine N-(2-methoxy-5-ethylphenyl)-N'-naphthylguanidine.